Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C

[1]  Yusuke Nakamura,et al.  ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients. , 2010, Gastroenterology.

[2]  K. Shianna,et al.  Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. , 2010, Gastroenterology.

[3]  R. D. de Knegt,et al.  Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C , 2010, Hepatology.

[4]  R. D. de Knegt,et al.  Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. , 2010, Journal of hepatology.

[5]  M. Repka,et al.  Ophthalmologic Complications in Children With Chronic Hepatitis C Treated With Pegylated Interferon , 2010, Journal of pediatric gastroenterology and nutrition.

[6]  S. Dhillon,et al.  Irreversible Pulmonary Hypertension Associated with the use of Interferon Alpha for Chronic Hepatitis C , 2010, Digestive Diseases and Sciences.

[7]  A. Andriulli,et al.  1185 ELTROMBOPAG IN CHRONIC LIVER DISEASE PATIENTS WITH THROMBOCYTOPENIA UNDERGOING AN ELECTIVE INVASIVE PROCEDURE: RESULTS FROM ELEVATE, A RANDOMISED CLINICAL TRIAL , 2010 .

[8]  Jacques Fellay,et al.  ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C , 2010, Nature.

[9]  J. Vecchiet,et al.  Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response , 2010, Journal of medical virology.

[10]  William M. Lee,et al.  Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. , 2009, The New England journal of medicine.

[11]  J. Lim,et al.  Pegylated-Interferon-Associated Retinopathy in Chronic Hepatitis Patients , 2009, Ophthalmologica.

[12]  A. Richetta,et al.  Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab , 2009, Dermatologic therapy.

[13]  J. I. Lee,et al.  Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin , 2009, Japanese Journal of Ophthalmology.

[14]  J. Hoofnagle,et al.  Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C. , 2009, Gastroenterology.

[15]  M. Hsieh,et al.  Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice , 2009, Alimentary pharmacology & therapeutics.

[16]  J. Drenth,et al.  Pneumonitis as A Consequence of (Peg)Interferon-Ribavirin Combination Therapy for Hepatitis C: a Review of the Literature , 2009, Digestive Diseases and Sciences.

[17]  M. Ghany,et al.  Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.

[18]  S. Khan,et al.  Effects of combined interferon alpha and ribavirin therapy on thyroid functions in patients with chronic hepatitis C. , 2009, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[19]  K. Reddy,et al.  Ribavirin: current role in the optimal clinical management of chronic hepatitis C. , 2009, Journal of hepatology.

[20]  Edward A Belongia,et al.  National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. , 2009, Annals of internal medicine.

[21]  P. Ferenci,et al.  Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C , 2008, Alimentary pharmacology & therapeutics.

[22]  M. A. D. do Carmo,et al.  Exacerbation of oral lichen planus lesions during treatment of chronic hepatitis C with pegylated interferon and ribavirin. , 2008, European journal of gastroenterology & hepatology.

[23]  S. Babudieri,et al.  Incidence of Neutropenia and Infections During Combination Treatment of Chronic Hepatitis C with Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin , 2008, Infection.

[24]  E. Mills,et al.  Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus. , 2008, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[25]  G. Tarantino,et al.  Do Thyroid Abnormalities Detected in Patients Treated for HCV-Related Chronic Hepatitis Persist? , 2008, International journal of immunopathology and pharmacology.

[26]  J. Blackard,et al.  Interferon alpha treatment and thyroid dysfunction. , 2007, Endocrinology and metabolism clinics of North America.

[27]  T. Berg,et al.  Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. , 2007, The New England journal of medicine.

[28]  J. Hoekstra,et al.  High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon α for chronic hepatitis C virus infection , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[29]  A. Heinz,et al.  Hepatitis C treatment in “difficult‐to‐treat” psychiatric patients with pegylated interferon‐alpha and ribavirin: Response and psychiatric side effects , 2007, Hepatology.

[30]  G. Usluer,et al.  Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection. , 2007, European journal of gastroenterology & hepatology.

[31]  M. Başkol,et al.  Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C. , 2007, European journal of gastroenterology & hepatology.

[32]  Y. Hashimoto,et al.  Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus , 2007, The Journal of dermatology.

[33]  R. Stravitz,et al.  Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha , 2007, Hepatology.

[34]  B. Bacon,et al.  Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. , 2007, The New England journal of medicine.

[35]  M. Sherman,et al.  Management of chronic hepatitis C: Consensus guidelines , 2007 .

[36]  H. Janssen,et al.  Severe allergic eczema due to pegylated alpha-interferon may abate after switching to daily conventional alpha-interferon. , 2007, Journal of clinical gastroenterology.

[37]  A. J. Thompson,et al.  The 5-HT3 receptor as a therapeutic target , 2007, Expert opinion on therapeutic targets.

[38]  L. Krahn,et al.  Modafinil’s Use in Combating Interferon-Induced Fatigue , 2007, Digestive Diseases and Sciences.

[39]  J. Piette,et al.  Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study. , 2006, Arthritis and rheumatism.

[40]  J. Jagirdar,et al.  Sarcoidosis after treatment with interferon-α: A case series and review of the literature , 2006 .

[41]  S. Akamatsu,et al.  Immune thrombocytopenia during interferon-alfa therapy for renal cell carcinoma. , 2006, Hinyokika kiyo. Acta urologica Japonica.

[42]  C. Cooper,et al.  Infection Rates in HIV-HCV Patients Treated with Interferon Are Similar to Those in HCV Mono-Infection and Not Related to Neutropenia , 2006, HIV clinical trials.

[43]  J. Mate,et al.  Chronic Hepatitis C and Crohn’s Disease: Nosocomial Infection Treatment with PEG-Interferon plus Ribavirin , 2006, Digestion.

[44]  H. Conjeevaram,et al.  Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. , 2006, Gastroenterology.

[45]  G. Garber,et al.  Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  M. Sernyak,et al.  Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders † , 2006, Journal of viral hepatitis.

[47]  S. Rosenberg,et al.  Hepatitis C treatment for people with severe mental illness. , 2006, Psychosomatics.

[48]  T. Asselah,et al.  Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C. , 2006, European journal of gastroenterology & hepatology.

[49]  Stefan Sleijfer,et al.  Side Effects of Interferon-α Therapy , 2005, Pharmacy World and Science.

[50]  R. Batey,et al.  The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with combination Interferon-α2β and Ribavirin , 2005, BMC endocrine disorders.

[51]  Colin W Shepard,et al.  Global epidemiology of hepatitis C virus infection. , 2005, The Lancet. Infectious diseases.

[52]  T. Mauro,et al.  Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature. , 2005, Archives of dermatology.

[53]  C. Datz,et al.  Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon α mono and combination therapy regimens , 2005, Gut.

[54]  T. Niewold,et al.  Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C , 2005, Clinical Rheumatology.

[55]  T. Pollmächer,et al.  Depression during therapy with interferon α - How long should an antidepressant treatment last? A case report , 2005 .

[56]  M. McKibbin,et al.  Is screening for interferon retinopathy in hepatitis C justified? , 2004, British Journal of Ophthalmology.

[57]  H. El‐Serag,et al.  Hepatocellular carcinoma: recent trends in the United States. , 2004, Gastroenterology.

[58]  J. Yoshikawa,et al.  Accelerated decline in lung function and impaired reversibility with salbutamol in asthmatic patients with chronic hepatitis C virus infection: a 6-year follow-up study. , 2004, The American journal of medicine.

[59]  M. Cappell.  Colonic Toxicity of Administered Drugs and Chemicals , 2004, American Journal of Gastroenterology.

[60]  R. Gish,et al.  Changes in haemoglobin during interferon alpha‐2b plus ribavirin combination therapy for chronic hepatitis C virus infection , 2004, Journal of viral hepatitis.

[61]  E. Schiff,et al.  Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. , 2004, Gastroenterology.

[62]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[63]  D Vergani,et al.  Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy , 2003, Alimentary pharmacology & therapeutics.

[64]  P. Laurberg,et al.  Interferon-alpha and autoimmune thyroid disease. , 2003, Thyroid : official journal of the American Thyroid Association.

[65]  I. Olivieri,et al.  Hepatitis C virus and arthritis. , 2003, Rheumatic diseases clinics of North America.

[66]  J. Hoofnagle,et al.  National institutes of health consensus development conference statement: Management of hepatitis C: 2002 — June 10–12, 2002 , 2002, Gastroenterology.

[67]  S. Dikman,et al.  Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. , 2002, Seminars in arthritis and rheumatism.

[68]  J. Hoofnagle,et al.  National institutes of health consensus development conference statement: Management of hepatitis C: 2002 — June 10–12, 2002 , 2002, HIV clinical trials.

[69]  J. Hoofnagle,et al.  Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C , 2002, Hepatology.

[70]  T. Singh,et al.  Aplastic anemia associated with interferon beta-1a. , 2002, American journal of therapeutics.

[71]  William M. Lee,et al.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. , 2002, Gastroenterology.

[72]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[73]  A. Borczuk,et al.  Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C , 2002, American Journal of Gastroenterology.

[74]  M. Rotondi,et al.  Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: A prospective study , 2002, Journal of endocrinological investigation.

[75]  P. Marcellin,et al.  Sarcoidosis during combined interferon alfa and ribavirin therapy in 2 patients with chronic hepatitis C. , 2002, Archives of dermatology.

[76]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[77]  서정헌,et al.  반도체 공정 overview , 2001 .

[78]  C. Sabin,et al.  The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985 , 2000, Gut.

[79]  G. Macedo,et al.  Interferon Plus Ribavirin: A Cautionary Note , 1999, American Journal of Gastroenterology.

[80]  A. Valleron,et al.  Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe , 1999, Journal of viral hepatitis.

[81]  F. Dimeo,et al.  Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy , 1999, Cancer.

[82]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[83]  K. Lindsay.  Therapy of hepatitis C: Overview , 1997, Hepatology.

[84]  T. Okanoue,et al.  Ischemic colitis during interferon-alpha treatment for chronic active hepatitis C , 1996, Journal of Gastroenterology.

[85]  K. Nishioka,et al.  Psoriasis and hepatitis C virus. , 1995, Acta dermato-venereologica.

[86]  G. V. van Rossum,et al.  A 6-year follow-up study of oral function in shortened dental arches. Part II: Craniomandibular dysfunction and oral comfort. , 1994, Journal of oral rehabilitation.

[87]  P. Marcellin,et al.  Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C , 1993, Clinical endocrinology.

[88]  P. Marcellin,et al.  Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C. , 1992, Gut.

[89]  R. Kerr.  A cautionary note. , 1988, Science.

[90]  J. Hoofnagle,et al.  Psychiatric complications of long-term interferon alfa therapy. , 1987, Archives of internal medicine.

[91]  Ronald S. Burt,et al.  A cautionary note , 1986 .

[92]  Nandi Ps,et al.  Recognition and management of acute pericarditis. , 1973 .

[93]  C. Pochedly.  Recognition and Management , 1971 .

[94]  S. Sungkanuparph,et al.  A CASE SERIES AND REVIEW OF THE LITERATURE , 2011 .

[95]  P. Hauser,et al.  Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia. , 2010, Schizophrenia bulletin.

[96]  C. Ríos-Bedoya,et al.  Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis. , 2008, Annals of hepatology.

[97]  William M. Lee,et al.  Hematologic Safety Data From the IDEAL Trial: Neutropenia, Anemia, and Thrombocytopenia Profiles of Peginterferon alfa/Ribavirin , 2008 .

[98]  K. Reddy,et al.  Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[99]  M. Sherman,et al.  Management of chronic hepatitis C: consensus guidelines. , 2007, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[100]  J. Manson,et al.  Prospective Study of , 2007 .

[101]  J. Peters,et al.  Sarcoidosis after treatment with interferon-alpha: a case series and review of the literature. , 2006, Respiratory medicine.

[102]  K. Hongo,et al.  A case report and review of the literature , 2006, Journal of Neuro-Oncology.

[103]  Andrew H. Miller,et al.  Neuropsychiatric adverse effects of interferon-alpha: recognition and management. , 2005, CNS drugs.

[104]  R. Dantzer,et al.  Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. , 2005, The Journal of clinical psychiatry.

[105]  T. Pollmächer,et al.  Depression during therapy with interferon alpha--how long should an antidepressant treatment last? , 2005, Pharmacopsychiatry.

[106]  A. Valentine,et al.  Neurobehavioral effects of interferon therapy , 2005, Current psychiatry reports.

[107]  S. Sleijfer,et al.  Side effects of interferon-alpha therapy. , 2005, Pharmacy world & science : PWS.

[108]  M. Ferraro,et al.  Generalised Dermatitis Induced by Pegylated Interferon-α-2b in a Patient Infected with Genotype-1 Hepatitis C Virus , 2005 .

[109]  F. Negro,et al.  Management of side effects of interferon alfa and ribavirin-based treatment of chronic hepatitis C , 2005 .

[110]  A. R.,et al.  Review of literature , 1969, American Potato Journal.

[111]  G. De Sarro,et al.  Generalised Dermatitis Induced by Pegylated Interferon-alpha-2b in a Patient Infected with Genotype-1 Hepatitis C Virus : Presentation of a Case. , 2005, Clinical drug investigation.

[112]  Andrew H. Miller,et al.  Neuropsychiatric Adverse Effects of Interferon-α , 2005 .

[113]  P. Marcellin,et al.  Tolerability of Treatments for Viral Hepatitis , 2001, Drug safety.

[114]  M. Manns,et al.  Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. , 1999, Journal of hepatology.

[115]  P. Cacoub,et al.  Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection. , 1999, Journal of hepatology.

[116]  S. van der Linden,et al.  Pericarditis after therapy with interferon-alpha for chronic hepatitis C. , 1999, Clinical rheumatology.

[117]  S. van der Linden,et al.  Pericarditis After Therapy with Interferon-α for Chronic Hepatitis C , 1999, Clinical Rheumatology.

[118]  P. Marcellin,et al.  Incidence of dysthyroidism during interferon therapy in chronic hepatitis C. , 1997, Hormone research.

[119]  G. Fattovich,et al.  A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. , 1996, Journal of hepatology.

[120]  K. Johnson.  An Update. , 1984, Journal of food protection.

[121]  J. Satyanarayana.  Recent trends in the United States market for Indian burlap , 1955 .

[122]  S. Antoniu.  of a consensus guidelines , 2022 .